⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL61971 | 1.00 | — | — | |
| SCHEMBL143955 | 1.00 | — | — | |
| SCHEMBL28651699 | 0.97 | — | — | |
| SCHEMBL27603922 | 0.97 | — | — | |
| SCHEMBL27743371 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL3590899 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL8686612 | 0.97 | — | — | |
| SCHEMBL27507066 | 0.97 | — | — | |
| Ammonia Solution, Strong SCHEMBL22437554 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL8686538 | 0.97 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 387 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1742608-A1 | NOVEL BIAROMATIC COMPOUNDS WHICH ACTIVATE PPAR&gammad;-TYPE RECEPTORS, THEIR PROCESS OF PREPARATION AND THEIR USE IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | Galderma Research & Development, S.N.C. (FR) | 2007-01-17 | — | — | EP | claimed |
| WO-2005108352-A1 | NOVEL BIAROMATIC COMPOUNDS WHICH ACTIVATE PPARϜ-TYPE RECEPTORS, THEIR PROCESS OF PREPARATION AND THEIR USE IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2005-11-17 | — | — | WO | claimed |
| EP-1377589-B1 | OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | PHARMACIA ITALIA SPA (IT) | 2005-09-07 | — | — | EP | claimed |
| WO-2026107328-A1 | AGONISTS OF PARATHYROID HORMONE 1 AND INCRETIN RECEPTORS | SEPTERNA, INC. (US) | 2026-05-21 | — | — | WO | disclosed |
| US-12577201-B2 | Glutamine analogs | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2026-03-17 | — | — | US | disclosed |
| EP-4707276-A2 | MALT1 MODULATORS AND USES THEREOF | Rarefied Biosciences, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| CN-116916924-B | MALT1 modulators and uses thereof | 稀有生物科学股份有限公司 | 2026-02-27 | — | — | CN | disclosed |
| EP-4229029-B1 | NOVEL GLUTAMINE ANALOGS | JACOBIO PHARMACEUTICALS CO LTD (CN) | 2026-02-25 | — | — | EP | disclosed |
| EP-4499611-B1 | MALT1 MODULATORS AND USES THEREOF | RAREFIED BIOSCIENCES INC (US) | 2026-02-18 | — | — | EP | disclosed |
| EP-4673150-A2 | COMPOSITIONS AND METHODS FOR TREATING MALT1 ASSOCIATED DISEASES | Rarefied Biosciences, Inc. (US) | 2026-01-07 | — | — | EP | disclosed |
| US-20250388589-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES, COMPOSITIONS AND USES THEREOF | DANATLAS PHARMACEUTICALS CO LTD (CN) | 2025-12-25 | — | — | US | disclosed |
| EP-1435948-A1 | AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | Pharmacia Italia S.p.A. (IT) | 2004-07-14 | — | — | EP | disclosed |
| WO-2003013517-A1 | AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | PHARMACIA ITALIA S.P.A. (IT) | 2003-02-20 | — | — | WO | disclosed |
| US-5731318-A | NEUROLOGICAL DISORDERS | BOEHRINGER INGELHEIM KG (DE) | 1998-03-24 | — | — | US | disclosed |
| US-5607941-A | BENZOMORPHAN DERIVATIVES | BOEHRINGER INGELHEIM KG (DE) | 1997-03-04 | — | — | US | disclosed |
| EP-0521422-B1 | Benzomorphanes and their use as pharmaceuticals | BOEHRINGER INGELHEIM KG (DE) | 1996-05-08 | — | — | EP | disclosed |
| EP-0532178-A1 | Methanoanthracenes as dopamine antagonists | ZENECA LIMITED (GB) | 1993-03-17 | — | — | EP | disclosed |
| EP-0521422-A1 | Benzomorphanes and their use as pharmaceuticals | BOEHRINGER INGELHEIM KG (DE) | 1993-01-07 | — | — | EP | disclosed |
| US-4874473-A | ADDING ADJUVANT TO CHANGE VAPOR PRESSURE, IMPROVE RESOLUTION | BAYER AKTIENGESELLSCHAFT (DE) | 1989-10-17 | — | — | US | disclosed |
| US-4845091-A | HYPOTENSIVE AGENTS, VASCULAR DISORDERS | CASSELLA AKTIENGESELLSCHAFT (DE) | 1989-07-04 | — | — | US | disclosed |